Drilldown/Medicines

None (1) · Mirabegron (1) · Quetiapine (1)

Myrbetriq (1) · Quviviq (1) · Seroquel (1)

Dual orexin receptor antagonist (DORA) (1) · [[:Category:Beta-3_agonists|β3 adrenergic agonist]] (1) · [[:Category:Dibenzothiazepines|Dibenzothiazepine]] (1) · [[:Category:Neuroleptics|Neuroleptic]] (1) · [[:Category:Overactive_bladder_medications|Overactive bladder medication]] (1) · [[:Category:Second-generation neuroleptics|Second-generation (atypical) neuroleptic]] (1) · [[:Category:Serotonin-dopamine antagonists|Serotonin-dopamine antagonist]] (1)

None (2) · Dopamine D2 and serotonin 5-HT2A receptor antagonist'"`UNIQ--ref-0000008D-QINU`"' '"`UNIQ--vote-0000008E-QINU`"' (1)

Insomnia (sleep onset and/or sleep maintenance) in adults (FDA-approved Jan 2022) (1) · '"`UNIQ--vote-0000008F-QINU`"', '"`UNIQ--vote-00000090-QINU`"', '"`UNIQ--vote-00000091-QINU`"', '"`UNIQ--vote-00000092-QINU`"' (1) · '"`UNIQ--vote-00000C4C-QINU`"', '"`UNIQ--vote-00000C4D-QINU`"' (1)

25 mg (schizophrenia, immediate-release); 50 mg (bipolar mania, immediate-release); 50 mg (Seroquel XR, schizophrenia or bipolar) (1) · 25 mg PO at bedtime (no titration); may increase to 50 mg if 25 mg inadequate (1) · 25 mg PO once daily; titrate to 50 mg after 4-8 weeks if needed (1)

25 mg, 50 mg tablets (1) · 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg immediate-release tablets; 50 mg, 150 mg, 200 mg, 300 mg, 400 mg extended-release tablets (Seroquel XR) (1) · 25, 50 mg ER tablets; 8 mg/mL granules for oral suspension (Myrbetriq Granules, pediatric) (1)

None · Indication-specific · 40 mg/d · 10 mg/d · 20 mg/d · 80 mg/d · 10 mg/d (adults) · 100 mg/d · 4 g/d · 400 mg/d · 40 mg/d typical; up to 240 mg/d for Zollinger-Ellison · 5 mg/d · 50 mg/d · 600 mg/d · No fixed ceiling; titrate to clinical effect and tolerability with CDC opioid prescribing guidance constraints on morphine-milligram-equivalent (MME) totals · No fixed maximum; titrated to TSH target · TID per eye · Titrated to glucose; no fixed ceiling · Titrated to glucose; no fixed maximum · '''20 mg/day in adults >60 years''' per FDA's 2011-2012 QT-prolongation warning; 40 mg/day in adults ≤60

Other values:

Search

Oral (3)

30-60 min (sedation); days to weeks (neuroleptic effect) (1) · Symptom improvement within weeks (1) · ~30 min (1)

24 hours (1) · 6-8 h (immediate-release); 24 h (extended-release) (1) · ~7-8 hours (1)

~50 hours'"`UNIQ--ref-00000C4E-QINU`"' (1) · ~6 h (parent compound, immediate-release); ~9-12 h (active metabolite N-desalkylquetiapine, also called norquetiapine) (1) · ~8 hours (shorter than suvorexant and lemborexant) (1)

25 mg: ~29%; 50 mg: ~35%; food reduces absorption'"`UNIQ--ref-00000C4F-QINU`"' (1) · Tablet ~100% relative to oral solution; extensive first-pass metabolism (1) · ~62% (1)

Limited data.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Limited data; avoid (1) · Pregnancy categories were retired by FDA in 2015. Quetiapine has reassuring active-comparator cohort data without consistent teratogenic signal; among the preferred neuroleptics when treatment is clinically necessary in pregnancy. See pregnancy_details for the full citation set. (1)

Rx, Schedule IV (US) (1) · [[USLegal:Prescription only|Prescription only]]; not a controlled substance (1) · [[USLegal:Prescription only|Rx-only]] in US (1)